$ANIK
Anika Therapeutics, Inc.

2019 Q4 Form 10-Q Financial Statement

#000117184319006886 Filed on October 28, 2019

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2018 Q4
Revenue $29.77M $29.70M $26.96M
YoY Change 10.45% 10.86% -8.28%
Cost Of Revenue $8.649M $5.951M $7.001M
YoY Change 23.54% -28.15% -19.68%
Gross Profit $21.12M $23.75M $19.95M
YoY Change 5.89% 28.36% -1.09%
Gross Profit Margin 70.95% 79.96% 74.01%
Selling, General & Admin $12.24M $7.539M $6.130M
YoY Change 99.67% 32.26% -8.23%
% of Gross Profit 57.95% 31.75% 30.73%
Research & Development $4.080M $4.158M $4.060M
YoY Change 0.49% -1.75% -4.92%
% of Gross Profit 19.32% 17.51% 20.35%
Depreciation & Amortization $1.530M $1.520M $1.480M
YoY Change 3.38% 0.66% 38.32%
% of Gross Profit 7.24% 6.4% 7.42%
Operating Expenses $16.32M $11.70M $10.19M
YoY Change 60.16% 17.77% -6.86%
Operating Profit $4.803M $12.05M $9.759M
YoY Change -50.78% 40.55% 5.75%
Interest Expense $360.0K $482.0K $550.0K
YoY Change -34.55% -7.66% 292.86%
% of Operating Profit 7.5% 4.0% 5.64%
Other Income/Expense, Net
YoY Change
Pretax Income $5.160M $12.53M $10.31M
YoY Change -49.95% 37.78% 4.46%
Income Tax $1.110M $3.300M $2.600M
% Of Pretax Income 21.51% 26.33% 25.22%
Net Earnings $4.051M $9.200M $7.717M
YoY Change -47.51% 21.07% -4.34%
Net Earnings / Revenue 13.61% 30.98% 28.63%
Basic Earnings Per Share $0.28 $0.65 $0.54
Diluted Earnings Per Share $0.28 $0.66 $0.54
COMMON SHARES
Basic Shares Outstanding 14.27M 14.07M
Diluted Shares Outstanding 14.62M 14.39M 14.30M

Balance Sheet

Concept 2019 Q4 2019 Q3 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $184.9M $173.2M $159.0M
YoY Change 16.29% 16.24% 1.08%
Cash & Equivalents $157.5M $103.4M $89.04M
Short-Term Investments $27.50M $69.80M $70.00M
Other Short-Term Assets $4.300M $1.500M $1.900M
YoY Change 126.32% -25.0% -40.63%
Inventory $22.00M $25.24M $21.30M
Prepaid Expenses
Receivables $23.08M $23.89M $20.78M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $234.3M $223.8M $202.9M
YoY Change 15.45% 14.43% -1.64%
LONG-TERM ASSETS
Property, Plant & Equipment $50.78M $51.75M $54.11M
YoY Change -6.15% -5.98% -3.69%
Goodwill $7.694M $7.489M $7.851M
YoY Change -2.0% -5.91% -4.47%
Intangibles $7.585M $7.680M $9.191M
YoY Change -17.47% -19.7% -13.58%
Long-Term Investments
YoY Change
Other Assets $7.478M $5.761M $4.897M
YoY Change 52.71% 419.48% 290.51%
Total Long-Term Assets $96.40M $95.76M $76.05M
YoY Change 26.76% 29.98% -0.31%
TOTAL ASSETS
Total Short-Term Assets $234.3M $223.8M $202.9M
Total Long-Term Assets $96.40M $95.76M $76.05M
Total Assets $330.7M $319.6M $279.0M
YoY Change 18.54% 18.69% -1.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.832M $2.702M $3.143M
YoY Change 21.92% 9.75% -53.42%
Accrued Expenses $12.40M $8.500M $8.100M
YoY Change 53.09% 25.0% 28.04%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.28M $11.20M $11.29M
YoY Change 44.18% 20.31% -13.65%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $357.0K $372.0K $550.0K
YoY Change -35.09% -35.19% -16.67%
Total Long-Term Liabilities $357.0K $372.0K $550.0K
YoY Change -35.09% -35.19% -16.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.28M $11.20M $11.29M
Total Long-Term Liabilities $357.0K $372.0K $550.0K
Total Liabilities $16.63M $11.57M $11.84M
YoY Change 40.5% 17.09% -13.79%
SHAREHOLDERS EQUITY
Retained Earnings $245.4M $241.4M $218.2M
YoY Change 12.46% 14.66% 9.38%
Common Stock $48.85M $46.63M $50.91M
YoY Change -4.04% -6.71% -25.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $288.4M $281.7M $263.6M
YoY Change
Total Liabilities & Shareholders Equity $330.7M $319.6M $279.0M
YoY Change 18.54% 18.69% -1.28%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2018 Q4
OPERATING ACTIVITIES
Net Income $4.051M $9.200M $7.717M
YoY Change -47.51% 21.07% -4.34%
Depreciation, Depletion And Amortization $1.530M $1.520M $1.480M
YoY Change 3.38% 0.66% 38.32%
Cash From Operating Activities $13.03M $10.05M $10.01M
YoY Change 30.17% -7.37% 43.41%
INVESTING ACTIVITIES
Capital Expenditures -$270.0K -$430.0K -$170.0K
YoY Change 58.82% -64.46% -93.12%
Acquisitions
YoY Change
Other Investing Activities $41.29M $2.530M -$2.420M
YoY Change -1806.2% -104.69% -238.29%
Cash From Investing Activities $41.02M $2.100M -$2.580M
YoY Change -1689.92% -103.81% 258.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 280.0K 21.70M -50.00K
YoY Change -660.0%
NET CHANGE
Cash From Operating Activities 13.03M 10.05M 10.01M
Cash From Investing Activities 41.02M 2.100M -2.580M
Cash From Financing Activities 280.0K 21.70M -50.00K
Net Change In Cash 54.33M 33.85M 7.380M
YoY Change 636.18% -176.41% 17.89%
FREE CASH FLOW
Cash From Operating Activities $13.03M $10.05M $10.01M
Capital Expenditures -$270.0K -$430.0K -$170.0K
Free Cash Flow $13.30M $10.48M $10.18M
YoY Change 30.65% -13.1% 7.72%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q3 anik Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
497000
CY2018Q4 anik Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
577000
CY2019Q3 anik Accrued Research Grants Current
AccruedResearchGrantsCurrent
381000
CY2018Q4 anik Accrued Research Grants Current
AccruedResearchGrantsCurrent
400000
CY2019Q3 anik Accumulated Currency Translation Adjustment
AccumulatedCurrencyTranslationAdjustment
4971000
CY2018Q4 anik Accumulated Currency Translation Adjustment
AccumulatedCurrencyTranslationAdjustment
4576000
anik Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-796000
anik Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
CY2019Q3 anik Inventory Raw Materials Work In Process And Finished Goods Net Of Reserve Total
InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal
30682000
CY2018Q4 anik Inventory Raw Materials Work In Process And Finished Goods Net Of Reserve Total
InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal
25133000
anik Operating Lease Rightofuse Asset Amortization
OperatingLeaseRightofuseAssetAmortization
880000
anik Operating Lease Rightofuse Asset Amortization
OperatingLeaseRightofuseAssetAmortization
CY2018Q4 anik Operating Leases Future Minimum Payments Due In Five Years And Thereafter
OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter
897000
CY2019Q3 anik Percentage Of Net Revenue
PercentageOfNetRevenue
1
CY2018Q3 anik Percentage Of Net Revenue
PercentageOfNetRevenue
1
anik Percentage Of Net Revenue
PercentageOfNetRevenue
1
anik Percentage Of Net Revenue
PercentageOfNetRevenue
1
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Document Period End Date
DocumentPeriodEndDate
2019-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000898437
CY2019Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
14269367
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
Anika Therapeutics, Inc.
dei Entity Shell Company
EntityShellCompany
false
dei Entity Small Business
EntitySmallBusiness
false
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
anik
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2702000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3143000
CY2019Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
23889000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
20775000
CY2019Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
766000
CY2018Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
385000
CY2019Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
8493000
CY2018Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
8146000
CY2019Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1333000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1989000
CY2019Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6318000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5526000
CY2019Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
46482000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
50763000
CY2019Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
124000
CY2019Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
120000
CY2018Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1736000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1386000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1443000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1311000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7565000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1322000
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1177000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1311000
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1177000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4140000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10064000
CY2019Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
981000
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1525000
CY2019Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000
CY2018Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
800000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
800000
CY2019Q3 us-gaap Assets
Assets
319579000
CY2018Q4 us-gaap Assets
Assets
278993000
CY2019Q3 us-gaap Assets Current
AssetsCurrent
223817000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
202943000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
132000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
197000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103381000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
89042000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
133256000
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81825000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
24279000
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
17648000
CY2018Q3 us-gaap Costs And Expenses
CostsAndExpenses
18214000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
14339000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-51431000
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14269000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14210000
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14269000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14210000
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
143000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
142000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
8578000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
7486000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
22350000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
10560000
CY2019Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
28000
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5951000
CY2018Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8282000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
20098000
us-gaap Costs And Expenses
CostsAndExpenses
55392000
us-gaap Costs And Expenses
CostsAndExpenses
66612000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
941000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1205000
CY2019Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
0
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
0
CY2019Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
4727000
CY2018Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
3542000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4459000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4433000
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.65
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.76
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.64
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.62
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.74
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
109000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
189000
CY2019Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.266
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.253
CY2018Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.164
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.147
CY2019Q3 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
300000
us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
400000
CY2019Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4039000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4446000
CY2019Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
15252000
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
14439000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-927000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-172000
CY2019Q3 us-gaap Goodwill
Goodwill
7489000
CY2018Q4 us-gaap Goodwill
Goodwill
7851000
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-362000
CY2018Q4 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
0
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
303000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
12531000
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
9095000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
30959000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
12894000
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3331000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7817000
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1496000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1890000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-335000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2449000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2751000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3136000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
377000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-158000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-681000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
509000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6600000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5891000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-440000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1304000
CY2019Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
28206000
CY2019Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7680000
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9191000
CY2019Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
482000
CY2018Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
522000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1513000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
907000
CY2019Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
10234000
CY2018Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6819000
CY2019Q3 us-gaap Inventory Net
InventoryNet
25243000
CY2018Q4 us-gaap Inventory Net
InventoryNet
21300000
CY2019Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
5439000
CY2018Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
3833000
CY2019Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
12686000
CY2018Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
13688000
CY2018Q1 us-gaap Inventory Recall Expense
InventoryRecallExpense
1100000
CY2017 us-gaap Inventory Recall Expense
InventoryRecallExpense
900000
CY2019Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
7762000
CY2018Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
4626000
us-gaap Inventory Write Down
InventoryWriteDown
1062000
us-gaap Inventory Write Down
InventoryWriteDown
4073000
us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
1075000
us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
CY2019Q3 us-gaap Lease Cost
LeaseCost
568000
us-gaap Lease Cost
LeaseCost
1729000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
23530000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1965000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1981000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2024000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2025000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
497000
CY2019Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9310000
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
319579000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
278993000
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
11195000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11289000
CY2019Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
69825000
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
69972000
us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellspacing="0" cellpadding="0" style="; font-size: 10pt; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 47px"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div></div></div></td> <td style="width: 7px">&nbsp;</td> <td style="text-align: justify"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">Nature of Business</div></div></td> </tr> </table> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Anika Therapeutics, Inc. (the &#x201c;Company&#x201d;) is a global, integrated joint preservation and regenerative therapies company based in Bedford, Massachusetts. The Company is committed to delivering innovative therapies to improve the lives of patients across a continuum of care from osteoarthritis pain management to joint preservation and restoration. The Company has over <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> decades of global expertise commercializing more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div> products based on its proprietary hyaluronic acid (&#x201c;HA&#x201d;) technology. The Company&#x2019;s therapeutic portfolio includes ORTHOVISC, MONOVISC, and CINGAL, viscosupplements which alleviate osteoarthritis pain and restore joint function by replenishing depleted HA, TACTOSET, a surgically-delivered therapy for bone repair procedures, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Company is subject to risks common to companies in the biotechnology and medical device industries including, but <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) and foreign regulations and approval requirements, as well as the ability to grow the Company&#x2019;s business through appropriate commercial strategies.</div></div>
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8420000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-28849000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1333000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-47676000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
23983000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
24905000
us-gaap Net Income Loss
NetIncomeLoss
23142000
us-gaap Net Income Loss
NetIncomeLoss
11004000
CY2019Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5761000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4897000
CY2019Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-622000
CY2018Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-113000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-792000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-444000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-315000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
9200000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
7599000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
4507000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
9435000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-6686000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
10091000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
12049000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
8573000
us-gaap Operating Income Loss
OperatingIncomeLoss
29446000
us-gaap Operating Income Loss
OperatingIncomeLoss
11987000
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
525000
us-gaap Operating Lease Cost
OperatingLeaseCost
1568000
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
22712000
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1109000
CY2018Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21603000
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
CY2019Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
488000
us-gaap Operating Lease Payments
OperatingLeasePayments
1482000
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23082000
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.041
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P17Y36D
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
8703000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1879000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
414000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1672000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1924000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1917000
CY2019Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
368000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
349000
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
145000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-622000
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
620000
CY2018Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-951000
CY2018Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-113000
CY2019Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
372000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
550000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
30000000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
30000000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
245000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1735000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
86368000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
77683000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2559000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4493000
CY2019Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1250000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1250000
CY2019Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1479000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1854000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
87594000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
34500000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
21825000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2886000
CY2019Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
0
CY2018Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
0
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
51750000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
54111000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-450000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-87000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4158000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4232000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12581000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14126000
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
241375000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
218233000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29697000
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26787000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
84838000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
78599000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
24110000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7539000
CY2018Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5700000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
22713000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
28207000
us-gaap Share Based Compensation
ShareBasedCompensation
4140000
us-gaap Share Based Compensation
ShareBasedCompensation
10064000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y182D
CY2019Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
us-gaap Short Term Lease Cost
ShortTermLeaseCost
6000
CY2019Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
CY2019Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
CY2019Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5000
CY2019Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
852000
CY2019Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
20967000
CY2018Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
512000
CY2018Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2375000
CY2019Q2 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
50000000
CY2019Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
30000000
CY2018Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
30000000
CY2018Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
1000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
281682000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
263612000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
269071000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
250946000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
263491000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
263766000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
246603000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
255265000
CY2019Q3 us-gaap Variable Lease Cost
VariableLeaseCost
43000
us-gaap Variable Lease Cost
VariableLeaseCost
155000
CY2019Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
317000
CY2018Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
140000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
201000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
296000
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14387000
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14377000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14266000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14820000
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14070000
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14237000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14065000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14524000

Files In Submission

Name View Source Status
0001171843-19-006886-index-headers.html Edgar Link pending
0001171843-19-006886-index.html Edgar Link pending
0001171843-19-006886.txt Edgar Link pending
0001171843-19-006886-xbrl.zip Edgar Link pending
anik-20190930.xml Edgar Link completed
anik-20190930.xsd Edgar Link pending
anik-20190930_cal.xml Edgar Link unprocessable
anik-20190930_def.xml Edgar Link unprocessable
anik-20190930_lab.xml Edgar Link unprocessable
anik-20190930_pre.xml Edgar Link unprocessable
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
f10q_102819p.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending